IDSA Recommendations for Preventing and Treating Bacterial Enteric Infections in HIV-AIDS Preventing Bacterial Enteric Illness: • Antimicrobial prophylaxis to prevent bacterial enteric illness usually is not recommended, including for travelers (AIII). • In rare cases, such as for immunosuppressed travelers, depending on their level of immunosuppression, the region of travel, and the trip’s duration, antimicrobial prophylaxis with fluoroquinolones or rifaximin can be considered (CIII). • For pregnant women and patients already on trimethoprim-sulfamethoxazole (TMP-SMX) for prophylaxis against Pneumocystis pneumonia TMP-SMX may offer limited protection against travelers’ diarrhea as an alternative to fluoroquinolone or rifaximin (BIII) Preferred Therapy for Salmonella Gastroenteritis With or Without Bacteremia: • Ciprofloxacin 500–750 mg PO (or 400 mg IV) q12h Preferred Therapy for Treating Shigellosis: • Ciprofloxacin 500–750 mg PO (or 400 mg IV) q12h if MIC<0.12 ug/ml Preferred Therapy for Treating Campylobacteriosis: • Ciprofloxacin 500–750 mg PO (or 400 mg IV) q12h Preferred Therapy for Treating Clostridium difficile Infection (CDI): • Vancomycin 125 mg (PO) 4 times per day for 10–14 days #Enteric #Bacterial #IDSA #Prevention #Treatment #management #opportunistic #infections #HIVAIDS #pharmacology
